SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROV	/AL
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

1. Name and Address of Reporting Person* Persson Magnus					2. Issuer Name and Ticker or Trading Symbol Avalo Therapeutics, Inc. [AVTX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
<u>r crsson magnus</u>				- H									Director			10% Ov	vner	
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 12/30/2022								Officer (give title below)			Other (specify below)		
C/O AVALO	THERAPE	EUTICS, INC.										_						
540 GAITHER ROAD, SUITE 400				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
														•	•	one Reportin	a Person	
(Street)														a 29 more	and r c		groloon	
ROCKVILLE	E MD	2	20850															
(City)	(State	;) (Zip)															
		1	able I - Nor	n-Deriva	tive S	ecuritie	s Acc	quired, D	isp	osed of	i, or Benefi	cially Ov	vned					
Date			2. Transac Date (Month/Day		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr.			ities Acquired (A) or d Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) or (D)	Price	(Instr. 3 an				(instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	Code	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisabl		expiration Date	Title	Amount or Number of Shares		(Instr. 4)	ion(s)			
Stock Option (Right to Buy)	\$5.0401	12/30/2022		A		2,536 ⁽¹⁾		12/30/2022	2 1	2/30/2032	Common Stock	2,536	\$0	2,53	6	D		

Explanation of Responses:

1. 100% of the stock option will immediately vest on the date that it is granted.

Remarks:

/s/ Christopher Sullivan, by Power	01/02/2022
of Attorney	01/03/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.